Ellis J Michael, Altman Michael D, Cash Brandon, Haidle Andrew M, Kubiak Rachel L, Maddess Matthew L, Yan Youwei, Northrup Alan B
Department of Discovery Chemistry, Merck & Co., Inc. , 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States.
ACS Med Chem Lett. 2016 Oct 7;7(12):1151-1155. doi: 10.1021/acsmedchemlett.6b00353. eCollection 2016 Dec 8.
Optimization of a series of highly potent and kinome selective carbon-linked carboxamide spleen tyrosine kinase (Syk) inhibitors with favorable drug-like properties is described. A pervasive Ames liability in an analogous nitrogen-linked carboxamide series was obviated by replacement with a carbon-linked moiety. Initial efforts lacked on-target potency, likely due to strain induced between the hinge binding amide and solvent front heterocycle. Consideration of ground state and bound state energetics allowed rapid realization of improved solvent front substituents affording subnanomolar Syk potency and high kinome selectivity. These molecules were also devoid of mutagenicity risk as assessed via the Ames test using the TA97a strain.
本文描述了一系列具有良好类药性质的高效且激酶组选择性碳连接羧酰胺脾酪氨酸激酶(Syk)抑制剂的优化过程。通过用碳连接部分取代,消除了类似氮连接羧酰胺系列中普遍存在的艾姆斯致突变性。最初的努力缺乏靶点活性,这可能是由于铰链结合酰胺和溶剂前沿杂环之间的应变所致。对基态和结合态能量学的考虑使得能够快速实现改进的溶剂前沿取代基,从而提供亚纳摩尔级别的Syk活性和高激酶组选择性。通过使用TA97a菌株的艾姆斯试验评估,这些分子也没有致突变风险。